Mylan acquires certain businesses from Famy Care

Pharma major Mylan today said its subsidiary Mylan Laboratories has completed acquisition of Famy Care to create a leading women's healthcare franchise.
"Mylan Laboratories has successfully completed the acquisition of certain women's healthcare businesses, now known as Jai Pharma, which were spun off from Famy Care Ltd," a company statement said here.
The acquisition will bring Mylan a broad women's care portfolio, strong technical capabilities and dedicated hormone manufacturing, which, when combined with Mylan's expansive global commercial footprint and supply chain infrastructure, it added.
Mylan CEO Heather Bresch commented, "In addition to strengthening our women's healthcare offering in North America, we will continue to leverage our powerful commercial platform in Europe, now enhanced through our recent Abbott deal, to serve this important therapeutic area.

The acquisition is expected to be immediately accretive to Mylan's adjusted diluted earnings per share and Mylan's financial leverage is not materially altered as a result of this transaction, it said.